| 产品名称： | Human herpesvirus 3 |
|---|---|
| 商品货号： | TS213774 |
| Classification： | Herpesviridae, Varicellovirus |
| Agent： | Human herpesvirus 3 |
| Strain： | Oka |
| Common Name： | Varicella zoster virus |
| Applications： | Virucide testing In vitro infectivity assay Antiviral Studies Spiking studies ELISpot Assay Virus neutralization assay Virus ultrastructural studies Immunological-based assays PCR-based assay validation Research and development Assay development Vaccine development |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen 1.0 mL per vial |
| Storage Conditions： | Vapor phase of liquid nitrogen |
| Images： |  |
| Comments： | Live, attenuated vaccine strain. Thermosensitive compared with other wild type strains. Depositor screened by Neurovirulence safety test, and result was compliant. |
| Effect on Host： | CPE, refractile rounding and degenration |
| Recommended Host： | MRC-5 cells (ATCC® CCL-171™) |
| Growth Conditions： | Temperature: 37°C Recommendations for Infection: Plate cells 16-24 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.01). Adsorb 1-2 hours at 37°C in a humidified x% CO2 atmosphere. End adsorption by adding virus growth medium. Replace virus growth medium at one day post-inoculation to remove DMSO from the culture. Harvest by removing culture medium and adding cell dissociation buffer. Dilute in freeze medium containing a final concentration of 7% DMSO and preserve with a controlled-rate freeze (1°C/minute). Incubation: 3-4 days at 37°C in a humidified 5% CO2 atmosphere, until CPE is progressed through 60% of the monolayer. |
| Source： | Y Oyabu, The Research Foundation for Microbial Diseases of Osaka University |
| References： | Takahashi M, et al. Development of a live attenuated varicella vaccine. Biken J. 18: 25-33, 1975. PubMed: 167707 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Human herpesvirus 3 |
|---|---|
| 商品货号： | TS213774 |
| Classification： | Herpesviridae, Varicellovirus |
| Agent： | Human herpesvirus 3 |
| Strain： | Oka |
| Common Name： | Varicella zoster virus |
| Applications： | Virucide testing In vitro infectivity assay Antiviral Studies Spiking studies ELISpot Assay Virus neutralization assay Virus ultrastructural studies Immunological-based assays PCR-based assay validation Research and development Assay development Vaccine development |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen 1.0 mL per vial |
| Storage Conditions： | Vapor phase of liquid nitrogen |
| Images： | |
| Comments： | Live, attenuated vaccine strain. Thermosensitive compared with other wild type strains. Depositor screened by Neurovirulence safety test, and result was compliant. |
| Effect on Host： | CPE, refractile rounding and degenration |
| Recommended Host： | MRC-5 cells (ATCC® CCL-171™) |
| Growth Conditions： | Temperature: 37°C Recommendations for Infection: Plate cells 16-24 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.01). Adsorb 1-2 hours at 37°C in a humidified x% CO2 atmosphere. End adsorption by adding virus growth medium. Replace virus growth medium at one day post-inoculation to remove DMSO from the culture. Harvest by removing culture medium and adding cell dissociation buffer. Dilute in freeze medium containing a final concentration of 7% DMSO and preserve with a controlled-rate freeze (1°C/minute). Incubation: 3-4 days at 37°C in a humidified 5% CO2 atmosphere, until CPE is progressed through 60% of the monolayer. |
| Source： | Y Oyabu, The Research Foundation for Microbial Diseases of Osaka University |
| References： | Takahashi M, et al. Development of a live attenuated varicella vaccine. Biken J. 18: 25-33, 1975. PubMed: 167707 |
